No benefit of Interfant protocols compared to BFM-based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina.
Carla Luciana PennellaMaría A DeuJorge G RossiEdgardo M BaialardoCristina N AlonsoPatricia RubioMyriam R GuitterCristian G Sánchez La RosaElizabeth M AlfaroPedro A ZubizarretaMaría S FelicePublished in: Pediatric blood & cancer (2020)
Interfant protocols and BFM-based protocols presented comparable results. The risk group stratification proposed by Interfant-06 was validated by our results, and MRD seems useful to identify patients with an increased risk of early relapse.